Thrombocytopenia

There are 67 papers on thrombocytopenia in aging research: 6 trials and 20 observational studies in people, 20 in animals, 12 reviews. The newest story, Nov 11, 2026: “Mildly low platelets alone linked to modest blood disease risk”.

Disease

67 papers study it36 more mention it32 findings

MeSH

10 new papers in 30 daysSee all 103 papers on thrombocytopenia

“thrombocytopenia, aphthous stomatitis, and diarrhoea also occurred more often in the everolimus group”
Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trialLancet (London, England)2011doi:10.1016/s0140-6736(10)62318-5
  • Human trial6
  • Humans20
  • Animals20
  • In silico1

Interventions

10

Navitoclax

upin reviews2upin cynomolgus monkeys1upin rats1

4 studies
  1. Navitoclax induces thrombocytopenia.

    “on-target toxicity (e.g., navitoclax-induced thrombocytopenia)”

    Review

    Senotherapy: scientific advances and clinical potential of senolytic therapies

    O Mundo da Saúde

  2. Navitoclax induces thrombocytopenia in young rats.

    “Moderate thrombocytopenia was induced by 10 mg/kg, and to a greater extent by 30 mg/kg.”

    Animalsin young ratsi.p.10 and 30 mg/kgmales

    The Senolytic Drug Navitoclax Protects the Brain After Experimental Ischemic Stroke

    Pharmaceuticals (Basel, Switzerland)

  3. Navitoclax increases thrombocytopenia (on-target toxicity).

    “ABT-263 is unlikely to be approved for the clinical treatment of solid tumors due to both on-target (thrombocytopenia) and off-target (neutropenia) toxicities”

    Reviewon-target toxicity

    Assessing the Complexities of Utilizing BH3 Mimetics for a Senolytic Strategy in Combination with Ionizing Radiation

    Radiation research

  4. Navitoclax induces thrombocytopenia in cynomolgus monkeys (intermittent treatment in aged monkeys) (modest, reversible).

    “Intermittent treatment with the senolytic navitoclax induced modest reversible thrombocytopenia; no serious drug-related toxicity was noted.”

    Animalsintermittent treatment in aged monkeys

    Navitoclax safety, tolerability, and effect on biomarkers of senescence and neurodegeneration in aged nonhuman primates

    Heliyon

More on Navitoclax

Olezarsen

upin humans1RR 2.24

1 study
  1. Olezarsen increases thrombocytopenia in humans (RR 2.24 [1.27, 3.96]).

    “Thrombocytopenia only increased with 80 mg (RR 2.24 [1.27, 3.96]; p=0.005).”

    Human trial80 mg12 months

    Dose-related effects of olezarsen in hypertriglyceridaemia: a systematic review and meta-analysis of 2,610 patients

    ESC Congress 2026 abstract

More on Olezarsen

Xenogeneic platelets

downin rodent1

1 study
  1. Xenogeneic platelets protect against thrombocytopenia in rodent.

    “platelets alleviated thrombocytopenia”

    Animals

    Functional xenogeneic hematopoietic cells maintaining donor-dominant identity and immune tolerance enable therapy

    Experimental hematology & oncology

More on Xenogeneic platelets

Senolytics

upin reviews1

1 study
  1. Senolytics induce thrombocytopenia (first-generation agents, dose-dependent).

    “these agents exhibited notable drawbacks, such as dose-dependent thrombocytopenia”

    Reviewfirst-generation agents, dose-dependent

    Emerging strategies in senotherapeutics: from broad-spectrum senolysis to precision reprogramming

    npj aging

More on Senolytics

Tirzepatide

upin humans1

1 study
  1. Tirzepatide is linked with thrombocytopenia in humans after dose increase to 12.5 mg.

    “Overall, these findings suggest an immune-mediated, drug-induced mechanism of severe thrombocytopenia.”

    Humansafter dose increase to 12.5 mg12.5 mgmalesn = 1

    A Rare Case of Tirzepatide-Associated Immune Thrombocytopenia

    Cureus

More on Tirzepatide

Orthotopic auxiliary partial liver xenotransplantation

upin rhesus monkeys1

1 study
  1. Orthotopic auxiliary partial liver xenotransplantation induces thrombocytopenia in rhesus monkeys following liver xenotransplantation (every recipient developed severe thrombocytopenia).

    “Strikingly, every recipient developed severe thrombocytopenia, graft thrombosis, and thrombotic microangiopathy, which ultimately culminated in graft dysfunction.”

    Animalsfollowing liver xenotransplantation6-, 8-, and 10-gene-edited porcine donors

    Multigene-Edited Pig-to-Rhesus-Macaque Liver Xenotransplantation: Multifaceted Profiling-of-Post-transplant Phenotypes

    Xenotransplantation

More on Orthotopic auxiliary partial liver xenotransplantation

Nicotinamide riboside

downin mice1

1 study
  1. Nicotinamide riboside protects against thrombocytopenia in mice under daily physiological stress.

    “6 weeks of NR supplementation protected against stress-induced thrombocytopenia”

    Animalsunder daily physiological stress6 weeks

    Nicotinamide riboside treatment enhances stress sensitivity and modulates hematological dynamics in aged mice

    GeroScience

More on Nicotinamide riboside

Nicotinamide

downin mice1

1 study
  1. Nicotinamide decreases thrombocytopenia in an ITP murine model.

    “Supplementation with NAD+ precursor nicotinamide (NAM), but not nicotinamide mononucleotide (NMN), increased Treg frequency and ameliorated thrombocytopenia in an ITP murine model”

    Animalsin an ITP murine model

    Nicotinamide enhances Treg differentiation by promoting Foxp3 acetylation in immune thrombocytopenia

    British journal of haematology

More on Nicotinamide

Nav-gal

downin mice1

1 study
  1. Nav-gal decreases thrombocytopenia in mice.

    “galacto-conjugation reduces Navitoclax-induced platelet apoptosis in human and murine blood samples treated ex vivo, and thrombocytopenia at therapeutically effective concentrations in murine lung cancer models.”

    Animalscompared with navitoclax; at therapeutically effective concentrations; murine lung cancer modelsgalacto-conjugated prodrug

    Galacto-conjugation of Navitoclax as an efficient strategy to increase senolytic specificity and reduce platelet toxicity

    Aging cell

More on Nav-gal

Caloric restriction

downin mice1

1 study
  1. Caloric restriction prevents thrombocytopenia in mice.

    “Thrombocytopenia was prevented by energy restriction in Group B6 mice.”

    Animals32% less energy from an otherwise comparable dietmalesn = 20

    Energy restriction prevents and reverses immune thrombocytopenic purpura (ITP) and increases life span of ITP-prone (NZW x BXSB) F1 mice

    The Journal of nutrition

More on Caloric restriction

Effects

2

Graft survival

downin reviews1

1 study
  1. Thrombocytopenia decreases graft survival.

    “Profound thrombocytopenia, consumptive coagulopathy, and xenotransplantation-associated thrombotic microangiopathy limit long-term graft survival.”

    Review

    Challenges and perspectives in xenoliver research: lessons from decedent and primate models

    Frontiers in transplantation

Overall survival

downin humans1HR 1.58

1 study
  1. Thrombocytopenia is linked with lower overall survival in humans (standard reference limits) (HR 1.58, 95% CI 1.32-1.89).

    “thrombocytopenia (HR, 1.58; 95% CI, 1.32-1.89), and, especially the concomitant presence of anemia and thrombocytopenia (HR, 4.75; 95% CI, 2.98-7.55) were associated with inferior overall survival.”

    Humansstandard reference limitsn = 167,729

    Peripheral blood cytopenias in the aging general population and risk of incident hematological disease and mortality

    Blood advances

Upstream

3

THBD

downin M. thibetana1

1 study
  1. THBD prevents thrombocytopenia in M. thibetana (pig-to-primate orthotopic liver xenotransplantation) (platelets >100 × 109/L in 3 of 4 recipients).

    “High expression of human thrombomodulin (hTBM) in donor livers effectively prevented early rapid and severe thrombocytopenia”

    Animalspig-to-primate orthotopic liver xenotransplantationlivern = 4

    Expression of Human Thrombomodulin Prevents Early Thrombocytopenia and Thrombotic Microangiopathy in Pig-to-Nonhuman Primate Orthotopic Liver Xenotransplantation

    Xenotransplantation

More on THBD

TXNIP

downin mice1

1 study
  1. TXNIP protects against thrombocytopenia in mice (Txnip deficiency).

    “Txnip-/- mice developed thrombocytopenia at 4 to 5 months that worsened with age.”

    AnimalsTxnip deficiency

    Deficiency of thioredoxin-interacting protein results in age-related thrombocytopenia due to megakaryocyte oxidative stress

    Journal of thrombosis and haemostasis : JTH

More on TXNIP

SPP1

downin mice1

1 study
  1. SPP1 protects against thrombocytopenia in mice.

    “aged OPN-/- bone marrow cells fail to adequately reconstitute red blood cells and platelets, resulting in severe anemia and thrombocytopenia”

    Animalsrecipients of aged osteopontin-knockout bone marrow cells in serial bone marrow transplantation

    Murine hematopoietic stem cell reconstitution potential is maintained by osteopontin during aging

    Scientific reports

More on SPP1

Associations

11

Mortality

upin humans3HR 5.7

3 studies
  1. Thrombocytopenia is associated with mortality in humans (Isolated mild or moderate-severe thrombocytopenia).

    “In both cohorts, the relative risk of death from any cause was increased in isolated mild”

    HumansIsolated mild or moderate-severe thrombocytopeniaMedian follow-up of 14 years in the UK and 11 years in Denmark

    Mildly low platelets alone linked to modest blood disease risk

    BMJ medicine

  2. Thrombocytopenia is linked with a higher risk of mortality in humans (COVID-19 and neuropsychiatric conditions) (HR 5.70, 95% CI 2.75-11.8).

    “thrombocytopenia (HR 5.70, 95% CI 2.75-11.8) independently increased the risk of mortality”

    HumansCOVID-19 and neuropsychiatric conditions40 daysn = 191

    Older patients with COVID-19 and neuropsychiatric conditions: A study of risk factors for mortality

    Brain and behavior

  3. Thrombocytopenia predicts mortality in humans (COVID-19).

    “In the multivariate logistic regression high CCI, low BI and thrombocytopenia remained to be predictors of death.”

    HumansCOVID-19n = 243

    Characteristics and risk factors for in-hospital mortality in 243 elderly patients with COVID-19 in Santorso, Italy: a retrospective study

    Advances in gerontology = Uspekhi gerontologii

Death from liver disease

upin humans1

1 study
  1. Thrombocytopenia is associated with death from liver disease in humans (UK individuals with isolated thrombocytopenia).

    “The relative risk of non-malignant liver disease, liver cancer, and death from liver disease was increased in UK individuals with isolated thrombocytopenia.”

    HumansUK individuals with isolated thrombocytopenia

    Mildly low platelets alone linked to modest blood disease risk

    BMJ medicine

Liver cancer

upin humans1

1 study
  1. Thrombocytopenia is associated with liver cancer in humans (UK individuals with isolated thrombocytopenia).

    “The relative risk of non-malignant liver disease, liver cancer, and death from liver disease was increased in UK individuals with isolated thrombocytopenia.”

    HumansUK individuals with isolated thrombocytopenia

    Mildly low platelets alone linked to modest blood disease risk

    BMJ medicine

More on Liver cancer

Nonmalignant liver disease

upin humans1

1 study
  1. Thrombocytopenia is associated with nonmalignant liver disease in humans (UK individuals with isolated thrombocytopenia) (Absolute risks <1–2% with normal platelet count, 2–4% with isolated mild thrombocytopenia, and 3–7% with isolated moderate-severe thrombocytopenia).

    “The relative risk of non-malignant liver disease, liver cancer, and death from liver disease was increased in UK individuals with isolated thrombocytopenia.”

    HumansUK individuals with isolated thrombocytopenia10 years

    Mildly low platelets alone linked to modest blood disease risk

    BMJ medicine

More on Nonmalignant liver disease

Death from hematological disease

upin humans1

1 study
  1. Thrombocytopenia is associated with death from hematological disease in humans (Isolated mild thrombocytopenia) (Absolute risk <1% across all age and sex categories with isolated mild thrombocytopenia).

    “the relative risk of haematological disease and death from haematological disease was increased in isolated mild or moderate-severe thrombocytopenia”

    HumansIsolated mild thrombocytopenia10 years

    Mildly low platelets alone linked to modest blood disease risk

    BMJ medicine

Hematologic disease

upin humans1

1 study
  1. Thrombocytopenia is associated with hematologic disease in humans (Isolated mild thrombocytopenia) (Absolute diagnosis risk ≤4% in UK individuals and ≤7% in Danish individuals versus ≤2% with normal platelet count and hemoglobin).

    “the relative risk of haematological disease and death from haematological disease was increased in isolated mild or moderate-severe thrombocytopenia”

    HumansIsolated mild thrombocytopenia10 years

    Mildly low platelets alone linked to modest blood disease risk

    BMJ medicine

More on Hematologic disease

Extracorporeal liver cross-circulation

upin humans1

1 study
  1. Extracorporeal liver cross-circulation raises the risk of thrombocytopenia in humans during five ELC procedures in four brain-dead human decedents.

    “We previously performed five ELC procedures in four brain-dead human decedents, during which the recipients developed severe thrombocytopenia.”

    Reviewduring five ELC procedures in four brain-dead human decedentsn = 4

    Longitudinal multiomics profiling of extracorporeal cross-circulation with pig liver xenografts in human decedents

    Nature medicine

More on Extracorporeal liver cross-circulation

Multidisciplinary mhealth rehabilitation

downin humans1

1 study
  1. Multidisciplinary mhealth rehabilitation lowers the risk of thrombocytopenia in humans (grade 1 or higher; abdominal cancer patients undergoing CCRT; compared with standard care) (16.1% vs. 34.6%).

    “lower incidences of ≥G3 leukopenia (5.4% vs. 19.2%, p=0.037) and ≥G1 thrombocytopenia (16.1% vs. 34.6%, p=0.026).”

    Human trialgrade 1 or higher; abdominal cancer patients undergoing CCRT; compared with standard caren = 111

    Multidisciplinary mHealth Rehabilitation Preserves Handgrip Strength and Muscle Mass During Abdominal Cancer Chemoradiotherapy: A Randomized Phase II Trial (Preprint)

    Preprint

More on Multidisciplinary mhealth rehabilitation

Frailty

upin humans1OR 11.13

1 study
  1. Frailty is linked with a higher risk of thrombocytopenia in humans (geriatric cancer patients receiving chemotherapy) (OR = 11.13, p = 0.021).

    “Frail geriatric patients with cancer were at higher risk of chemotherapy-related adverse outcomes, such as grades 3-4 thrombocytopenia (odds ratio [OR] = 11.13, p = 0.021)”

    Humansgeriatric cancer patients receiving chemotherapywithin 3 months of treatmentn = 234

    Association of frailty and chemotherapy-related adverse outcomes in geriatric patients with cancer: a pilot observational study in Taiwan

    Aging

Everolimus

upin humans1

1 study
  1. Everolimus raises the risk of thrombocytopenia in humans (versus ciclosporin-based regimen).

    “thrombocytopenia, aphthous stomatitis, and diarrhoea also occurred more often in the everolimus group”

    Human trialversus ciclosporin-based regimen

    Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial

    Lancet (London, England)

More on Everolimus

Navitoclax

upin humans1

1 study
  1. Navitoclax raises the risk of thrombocytopenia in humans (29 patients).

    “Thrombocytopenia and neutropenia were the serious common toxicities with grade 3 or 4 thrombocytopenia or neutropenia observed in 29 and 17 patients, respectively.”

    Human trialn = 55

    Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

    The Lancet. Oncology

More on Navitoclax

Trial sponsors

Funding

1 grant since 2019

Agence Nationale de la Recherche€564K

Latest

Dec 2025: 1Jan 2026: 6Feb 2026: 5Mar 2026: 7Apr 2026: 4May 2026: 4Jun 2026: 0Jul 2026: 7Aug 2026: 1Sep 2026: 3Oct 2026: 3Nov 2026: 748 papers in 12 months
BMJ Medicine

Mildly low platelets alone linked to modest blood disease risk

Ten-year blood disease risks were at most 4% in UK adults and 7% in Denmark, versus at most 2% with normal platelet and hemoglobin levels.Ten-year blood disease risks were at most 4% in UK adults and 7% in Denmark, versus at most 2% with normal platelet and hemoglobin levels.

Cohort · 485,103 peopleHematologic disease
AHA Scientific Sessions 2026 Abstract

Gene variants linked to higher odds of fatty liver disease

In 402,437 people, variants disrupting one copy of a fat-transport gene were linked to higher fatty liver odds, with an odds ratio of 3.2 versus non-carriers.In 402,437 people, variants disrupting one copy of a fat-transport gene were linked to higher fatty liver odds, with an odds ratio of 3.2 versus non-carriers.

Genetic association · 402,437 peopleMechanisms
ESC Congress 2026 Abstract

Targeted drug carriers reduced artery calcium buildup in mice

Tiny carriers delivered two cell-clearing drugs in two mouse models, improving survival and avoiding blood-cell side effects associated with dasatinib given without…Tiny carriers delivered two cell-clearing drugs in two mouse models, improving survival and avoiding blood-cell side effects associated with dasatinib given without carriers.

Mouse studyInterventions

See all 103 papers on thrombocytopenia